Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HRS-5041 |
| Synonyms | |
| Therapy Description |
HRS-5041 is an androgen receptor (AR) degrader with activity against wild-type and mutant AR, which potentially induces antitumor activity (J Clin Oncol 2026 44: 16_Suppl, 3112). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HRS-5041 | HRS 5041|HRS5041 | Hormone - Anti-androgens 59 | HRS-5041 is an androgen receptor (AR) degrader with activity against wild-type and mutant AR, which potentially induces antitumor activity (J Clin Oncol 2026 44: 16_Suppl, 3112). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06830850 | Phase I | HRS-5041 | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | AUS | 0 |